Free Trial

Autolus Therapeutics Q4 2024 Earnings Report

Autolus Therapeutics logo
$1.52 -0.05 (-3.18%)
As of 01:34 PM Eastern

Autolus Therapeutics EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.21
Beat/Miss
Beat by +$0.12
One Year Ago EPS
N/A

Autolus Therapeutics Revenue Results

Actual Revenue
$0.03 million
Expected Revenue
$2.98 million
Beat/Miss
Missed by -$2.95 million
YoY Revenue Growth
N/A

Autolus Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Remove Ads

Autolus Therapeutics Earnings Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
Autolus Therapeutics price target lowered to $10 from $11 at Truist
FY2028 Earnings Estimate for AUTL Issued By William Blair
See More Autolus Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Autolus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Autolus Therapeutics and other key companies, straight to your email.

About Autolus Therapeutics

Autolus Therapeutics (NASDAQ:AUTL), a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

View Autolus Therapeutics Profile

More Earnings Resources from MarketBeat